Hemab Therapeutics Holdings, Inc. Common Stock

NASDAQ:COAG

Biotechnology

Healthcare
$39.15 +8.79%

+$2.32 today

Market cap
$1.83B
Beta
0.00
52W Low $23.00High $36.61

Volume 0.30M

Average 0.34M

COAG Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Hemab Therapeutics Holdings, Inc. Common StockNASDAQ: COAG

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue of $0 in Q2 FY2026

Q2 FY2026 revenue was $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Revenue vs competitors

How COAG compares with its peers on the latest reported figures

  • COAG's FY2025 revenue of $0 is the 3rd highest of the 5 companies compared; the peer median is $429K.
COAG Competitors Peer median
Revenue for COAG and competitors
Company Period LTM YoY 3-year CAGR
QUREuniQure N.V.LTM Mar 2026$18.09M -10.4%-46.7%
RLYBRallybio CorporationLTM Mar 2026$858K +1.2%—
COAGHemab Therapeutics Holdings, Inc. Common StockFY2025$0 ——
IRONDisc Medicine, Inc.LTM Sep 2026$0 ——
DMRADamora Therapeutics, Inc.LTM Mar 2026$0 ——
Peer median (excluding COAG) $429K-4.6%-46.7%

Competitors are the stored peer set for COAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Hemab Therapeutics Holdings, Inc. Common Stock

NASDAQ:COAG

Intrinsic Alpha fair value

Locked

Current Price

$39.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.